AMGN vs FBRX
AMGN: A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures. FBRX: A clinical-stage biotech developing an anti-CD122 antibody (FB102) to modulate immune cells in autoimmune diseases, with promising early celiac disease data and trials underway in vitiligo and alopecia areata.
Side-by-side fundamentals
| Metric | AMGN | FBRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $366.05 | $56.63 | |
| Market cap as of 2026-07-23 | $197.7B | $1.2B | |
| P/E as of 2026-07-23 | 25.34 | n/a | |
| PEG as of 2026-07-23 | 4.93 | n/a | |
| Net margin as of 2026-07-23 | +21.0% | -158775.0% | AMGN higher |
| Gross margin as of 2026-07-23 | +74.0% | n/a | |
| Operating margin as of 2026-07-23 | +28.8% | -150175.0% | AMGN higher |
| ROE as of 2026-07-23 | +89.4% | -106.2% | AMGN higher |
| ROA as of 2026-07-23 | +8.6% | -85.5% | AMGN higher |
| Debt / equity as of 2026-07-23 | 6.24 | 0.00 | FBRX lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.1% | -99.8% | AMGN higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | -9.8% | AMGN higher |
| Dividend yield as of 2026-07-23 | +2.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.43 | 2.83 | |
| 1-year return as of 2026-07-22 close | +19.7% | +401.8% | FBRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.